Skip to main content

Table 2 Evaluation of the relationship between global scales and regional neuropathologic measures with plasma p-tau181and p-tau217 levels

From: Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

 

MSD plasma

p-tau181

MSD plasma

p-tau217

Global scales

R (p-value)

R (p-value)

 Braak stage

0.45 (0.008)

0.48 (0.004)

 Thal phase

0.57 (< 0.001)

0.71 (< 0.001)

 Diffuse plaques score

0.44 (0.009)

0.64 (< 0.001)

 Neuritic plaques score

0.39 (0.024)

0.57 (< 0.001)

 LATE-NC stage

0.13 (0.464)

0.16 (0.379)

 Kalaria CVD score

0.32 (0.067)

0.27 (0.119)

Regional measures

R (p-value)

R (p-value)

 Hippocampal pT181

0.37 (0.054)

0.43 (0.023)

 Hippocampal pT217

0.30 (0.087)

0.28 (0.113)

 Hippocampal 6F/3D

0.41 (0.018)

0.46 (0.007)

 Parietal pT181

0.55 (0.003)

0.55 (0.003)

 Parietal pT217

0.55 (< 0.001)

0.66 (< 0.001)

 Parietal 6F/3D

0.59 (< 0.001)

0.71 (< 0.001)

 LC neurons/mm2

−0.50 (0.007)

−0.55 (0.002)

 nbM neurons/mm2

−0.10 (0.663)

−0.18 (0.418)

  1. Spearman correlation data presented with correlation coefficient (R) and significance (p-value). Case with high creatinine was not included. Acronyms: CAA Cerebral amyloid angiopathy, CVD Cerebrovascular disease, LATE-NC Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change, LC Locus coeruleus, MSD Meso scale discovery, nbM nucleus basalis of Meynert, p-tau phosphorylated tau in plasma, pT phosphorylated threonine for immunohistochemical measures of tau
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326